Abiomed's Impella Shows Heart Function, Symptom Improvements For High-Risk PCI Patients

Vandana Singh
1 min read
0
In this article:

  • Abiomed Inc's (NASDAQ: ABMD) Restore EF study demonstrated that Impella-supported high-risk percutaneous coronary intervention (PCI) leads to significant improvements in left ventricular ejection fraction (LVEF), angina symptoms, and heart failure symptoms at follow-up.

  • A 29% relative improvement from baseline LVEF (n=251, p<0.0001), with a significantly greater improvement in LVEF for those who had complete revascularization.

  • Significant improvement in heart failure symptoms was observed, with an overall 76% reduction in heart failure symptoms.

  • Significant improvement in angina symptoms, with an overall 97% reduction in angina symptoms.

  • Participants with higher baseline LVEF (greater than 45%) also experienced significant symptomatic improvement, similar to patients with lower LVEF.

  • Restore EF and the PROTECT III study further demonstrate the safety and benefits.

  • PROTECT III shows reduced MACCE rates compared to PROTECT II (15.1% vs. 21.9%) when Impella is used to achieve more complete revascularization in a single setting for high-risk PCI patients.

  • Operators from the community and academic centers demonstrated low major bleeding rates of 2.5% in the Restore EF study and 1.8% in the PROTECT III study when contemporary best practices were followed.

  • Price Action: ABMD shares are down 1.41% at $290.90 during the market session on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories